The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

What's known on the subject? and What does the study add? A growing body of evidence supports the anti‐cancer effect of histone deacetylase inhibitors (HDACi) in vitro, via multiple pathways, and many Phase I clinical trials have shown them to be well‐tolerated in a range of malignancies. Combi...

Full description

Saved in:

Bibliographic Details
Published in:	BJU international Vol. 111; no. 4; pp. 537 - 542
Main Authors:	Sharma, Naomi L., Groselj, Blaz, Hamdy, Freddie C., Kiltie, Anne E.
Format:	Journal Article
Language:	English
Published:	Oxford Wiley-Blackwell 01.04.2013
Subjects:	Animals Antineoplastic Agents - therapeutic use Biological and medical sciences cancer Clinical Trials as Topic Combined Modality Therapy combined therapy Disease Models, Animal HDAC inhibitor Histone Deacetylase Inhibitors - therapeutic use Histone Deacetylases - drug effects Histone Deacetylases - genetics Humans In Vitro Techniques Male Medical sciences Molecular Targeted Therapy - methods Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nephrology. Urinary tract diseases Prognosis Prospective Studies Radiotherapy, Adjuvant Risk Assessment Survival Rate Treatment Outcome Tumors Urologic Neoplasms - drug therapy Urologic Neoplasms - genetics Urologic Neoplasms - mortality Urologic Neoplasms - pathology urology combined therapy Histone deacetylase Histone deacetylase inhibitor Nephrology Urinary system HDAC inhibitor Combined treatment Malignant tumor Urinary tract Urology Cancer
ISSN:	1464-4096, 1464-410X, 1464-410X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!